Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Other Non Operating Income (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Non Operating Income for 11 consecutive years, with -$42.3 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 413.62% to -$42.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$34.5 million through Dec 2025, down 207.85% year-over-year, with the annual reading at -$42.8 million for FY2025, 417.38% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$42.3 million at ImmunityBio, down from $289000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $21.2 million in Q2 2024, with the low at -$42.3 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$2.1 million, with a median of $12000.0 recorded in 2024.
  • The sharpest move saw Other Non Operating Income soared 75792.86% in 2024, then crashed 413.62% in 2025.
  • Over 5 years, Other Non Operating Income stood at -$252000.0 in 2021, then soared by 102.38% to $6000.0 in 2022, then tumbled by 567616.67% to -$34.1 million in 2023, then surged by 139.58% to $13.5 million in 2024, then plummeted by 413.62% to -$42.3 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$42.3 million, $289000.0, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.